Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats
- PMID: 15225634
- DOI: 10.1016/j.febslet.2004.05.066
Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats
Abstract
Administration of interleukin-15 (IL-15) to rats bearing the Yoshida AH-130 ascites hepatoma (a tumour that induces an important cachectic response) resulted in a significant reduction of muscle wasting, both measured as muscle weight and as protein content of different types of skeletal muscle. In addition, the administration of the cytokine completely reversed the increased DNA fragmentation observed in skeletal muscle of tumour-bearing animals. Concerning the mechanism(s) involved in the anti-apoptotic effects of IL-15 on skeletal muscle, the administration of the cytokine resulted in a considerable decrease in both R1 (43%) and R2 (64%) TNF-alpha receptors (TNFRs), and therefore it may be suggested that IL-15 decreases apoptosis by affecting TNF-alpha signalling. Formation of NO could be the signalling event associated with the activation of apoptosis in muscle of tumour-bearing rats; indeed, administration of IL-15 decreased the inducible nitric oxide synthase protein levels by 73%, suggesting that NO formation and muscle apoptosis during tumour growth are related. In conclusion, IL-15 seems to be able to reduce/suppress protein loss and apoptosis related to muscle wasting during cancer cachexia in experimental animals.
Similar articles
-
Selective up-regulation of tumor necrosis factor receptor I in tumor-bearing rats with cancer-related cachexia.Int J Oncol. 2003 Aug;23(2):429-36. Int J Oncol. 2003. PMID: 12851692
-
Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue.Int J Oncol. 2005 Sep;27(3):855-60. Int J Oncol. 2005. PMID: 16077938
-
Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats.Br J Cancer. 2000 Aug;83(4):526-31. doi: 10.1054/bjoc.2000.1299. Br J Cancer. 2000. PMID: 10945502 Free PMC article.
-
Waste management - cytokines, growth factors and cachexia.Cytokine Growth Factor Rev. 2006 Dec;17(6):475-86. doi: 10.1016/j.cytogfr.2006.09.006. Epub 2006 Nov 22. Cytokine Growth Factor Rev. 2006. PMID: 17118696 Review.
-
The divergent effects of tumour necrosis factor-alpha on skeletal muscle: implications in wasting.Eur Cytokine Netw. 2000 Dec;11(4):552-9. Eur Cytokine Netw. 2000. PMID: 11125297 Review.
Cited by
-
Exercise protects vascular function by countering senescent cells in older adults.Front Physiol. 2023 Apr 6;14:1138162. doi: 10.3389/fphys.2023.1138162. eCollection 2023. Front Physiol. 2023. PMID: 37089434 Free PMC article. Review.
-
Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management.Nat Rev Clin Oncol. 2023 Apr;20(4):250-264. doi: 10.1038/s41571-023-00734-5. Epub 2023 Feb 20. Nat Rev Clin Oncol. 2023. PMID: 36806788 Review.
-
Exercise as a therapy for cancer-induced muscle wasting.Sports Med Health Sci. 2020 Dec 3;2(4):186-194. doi: 10.1016/j.smhs.2020.11.004. eCollection 2020 Dec. Sports Med Health Sci. 2020. PMID: 35782998 Free PMC article. Review.
-
Skeletal Muscle Deconditioning in Breast Cancer Patients Undergoing Chemotherapy: Current Knowledge and Insights From Other Cancers.Front Cell Dev Biol. 2021 Sep 14;9:719643. doi: 10.3389/fcell.2021.719643. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34595171 Free PMC article. Review.
-
Phenotypic features of cancer cachexia-related loss of skeletal muscle mass and function: lessons from human and animal studies.J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):252-273. doi: 10.1002/jcsm.12678. Epub 2021 Mar 30. J Cachexia Sarcopenia Muscle. 2021. PMID: 33783983 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
